The Effectiveness of Cross-Tapering Switching to Ziprasidone in Patients with Schizophrenia or Schizoaffective Disorder
Switching antipsychotics is one useful therapeutic option when the treatment of schizophrenia encounters suboptimal efficacy and intolerability issues. This study aimed to investigate the efficacy and tolerability of cross-tapering switching to ziprasidone from other antipsychotics. A total of 67 pa...
Saved in:
| Published in | Psychiatry investigation Vol. 11; no. 4; pp. 459 - 466 |
|---|---|
| Main Authors | , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Korea (South)
Korean Neuropsychiatric Association
01.10.2014
대한신경정신의학회 |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1738-3684 1976-3026 |
| DOI | 10.4306/pi.2014.11.4.459 |
Cover
| Abstract | Switching antipsychotics is one useful therapeutic option when the treatment of schizophrenia encounters suboptimal efficacy and intolerability issues. This study aimed to investigate the efficacy and tolerability of cross-tapering switching to ziprasidone from other antipsychotics.
A total of 67 patients with schizophrenia or schizoaffective disorder were recruited in this 12-week, multicenter, non-comparative, open-label trial. Prior antipsychotics were allowed to be maintained for up to 4 weeks during the titration of ziprasidone. Efficacy was primarily measured using the 18-item Brief Psychotic Rating Scale (BPRS) at baseline, 4 weeks, 8 weeks, and 12 weeks. Efficacy was secondarily measured by the Clinical Global Impression-Severity (CGI-S) scale and the Global Assessment of Functioning (GAF) scale at each visit. Regarding the metabolic effects of switching to ziprasidone, weight, body mass index (BMI), waist-to-hip ratio (WHR), and lipid profile-including triglyceride (TG), high-density lipoprotein (HDL), low-density lipoprotein (LDL), and total cholesterol levels-were measured at each follow-up visit.
The BPRS scores were significantly improved at 12 weeks after switching to ziprasidone (F=5.96, df=2.11, p=0.003), whereas the CGI-S and GAF scores were not significantly changed. BMIs, WHRs, and TG levels were significantly decreased, with no significant changes in other lipid profiles.
Cross-tapering switching to ziprasidone is effective for patients with schizophrenia spectrum disorders. Beyond the efficacy of the procedure, favorable metabolic profiles show that switching to ziprasidone may be helpful for maintenance therapy over an extended period. |
|---|---|
| AbstractList | Switching antipsychotics is one useful therapeutic option when the treatment of schizophrenia encounters suboptimal efficacy and intolerability issues. This study aimed to investigate the efficacy and tolerability of cross-tapering switching to ziprasidone from other antipsychotics.
A total of 67 patients with schizophrenia or schizoaffective disorder were recruited in this 12-week, multicenter, non-comparative, open-label trial. Prior antipsychotics were allowed to be maintained for up to 4 weeks during the titration of ziprasidone. Efficacy was primarily measured using the 18-item Brief Psychotic Rating Scale (BPRS) at baseline, 4 weeks, 8 weeks, and 12 weeks. Efficacy was secondarily measured by the Clinical Global Impression-Severity (CGI-S) scale and the Global Assessment of Functioning (GAF) scale at each visit. Regarding the metabolic effects of switching to ziprasidone, weight, body mass index (BMI), waist-to-hip ratio (WHR), and lipid profile-including triglyceride (TG), high-density lipoprotein (HDL), low-density lipoprotein (LDL), and total cholesterol levels-were measured at each follow-up visit.
The BPRS scores were significantly improved at 12 weeks after switching to ziprasidone (F=5.96, df=2.11, p=0.003), whereas the CGI-S and GAF scores were not significantly changed. BMIs, WHRs, and TG levels were significantly decreased, with no significant changes in other lipid profiles.
Cross-tapering switching to ziprasidone is effective for patients with schizophrenia spectrum disorders. Beyond the efficacy of the procedure, favorable metabolic profiles show that switching to ziprasidone may be helpful for maintenance therapy over an extended period. Switching antipsychotics is one useful therapeutic option when the treatment of schizophrenia encounters suboptimal efficacy and intolerability issues. This study aimed to investigate the efficacy and tolerability of cross-tapering switching to ziprasidone from other antipsychotics.OBJECTIVESwitching antipsychotics is one useful therapeutic option when the treatment of schizophrenia encounters suboptimal efficacy and intolerability issues. This study aimed to investigate the efficacy and tolerability of cross-tapering switching to ziprasidone from other antipsychotics.A total of 67 patients with schizophrenia or schizoaffective disorder were recruited in this 12-week, multicenter, non-comparative, open-label trial. Prior antipsychotics were allowed to be maintained for up to 4 weeks during the titration of ziprasidone. Efficacy was primarily measured using the 18-item Brief Psychotic Rating Scale (BPRS) at baseline, 4 weeks, 8 weeks, and 12 weeks. Efficacy was secondarily measured by the Clinical Global Impression-Severity (CGI-S) scale and the Global Assessment of Functioning (GAF) scale at each visit. Regarding the metabolic effects of switching to ziprasidone, weight, body mass index (BMI), waist-to-hip ratio (WHR), and lipid profile-including triglyceride (TG), high-density lipoprotein (HDL), low-density lipoprotein (LDL), and total cholesterol levels-were measured at each follow-up visit.METHODSA total of 67 patients with schizophrenia or schizoaffective disorder were recruited in this 12-week, multicenter, non-comparative, open-label trial. Prior antipsychotics were allowed to be maintained for up to 4 weeks during the titration of ziprasidone. Efficacy was primarily measured using the 18-item Brief Psychotic Rating Scale (BPRS) at baseline, 4 weeks, 8 weeks, and 12 weeks. Efficacy was secondarily measured by the Clinical Global Impression-Severity (CGI-S) scale and the Global Assessment of Functioning (GAF) scale at each visit. Regarding the metabolic effects of switching to ziprasidone, weight, body mass index (BMI), waist-to-hip ratio (WHR), and lipid profile-including triglyceride (TG), high-density lipoprotein (HDL), low-density lipoprotein (LDL), and total cholesterol levels-were measured at each follow-up visit.The BPRS scores were significantly improved at 12 weeks after switching to ziprasidone (F=5.96, df=2.11, p=0.003), whereas the CGI-S and GAF scores were not significantly changed. BMIs, WHRs, and TG levels were significantly decreased, with no significant changes in other lipid profiles.RESULTSThe BPRS scores were significantly improved at 12 weeks after switching to ziprasidone (F=5.96, df=2.11, p=0.003), whereas the CGI-S and GAF scores were not significantly changed. BMIs, WHRs, and TG levels were significantly decreased, with no significant changes in other lipid profiles.Cross-tapering switching to ziprasidone is effective for patients with schizophrenia spectrum disorders. Beyond the efficacy of the procedure, favorable metabolic profiles show that switching to ziprasidone may be helpful for maintenance therapy over an extended period.CONCLUSIONCross-tapering switching to ziprasidone is effective for patients with schizophrenia spectrum disorders. Beyond the efficacy of the procedure, favorable metabolic profiles show that switching to ziprasidone may be helpful for maintenance therapy over an extended period. Objective Switching antipsychotics is one useful therapeutic option when the treatment of schizophrenia encounters suboptimal efficacy and intolerability issues. This study aimed to investigate the efficacy and tolerability of cross-tapering switching to ziprasidone from other antipsychotics. Methods A total of 67 patients with schizophrenia or schizoaffective disorder were recruited in this 12-week, multicenter, non-comparative, open-label trial. Prior antipsychotics were allowed to be maintained for up to 4 weeks during the titration of ziprasidone. Efficacy was primarily measured using the 18-item Brief Psychotic Rating Scale (BPRS) at baseline, 4 weeks, 8 weeks, and 12 weeks. Efficacy was secondarily measured by the Clinical Global Impression-Severity (CGI-S) scale and the Global Assessment of Functioning (GAF) scale at each visit. Regarding the metabolic effects of switching to ziprasidone, weight, body mass index (BMI), waist-to-hip ratio (WHR), and lipid profile–including triglyceride (TG), high-density lipoprotein (HDL), low-density lipoprotein (LDL), and total cholesterol levels–were measured at each follow-up visit. Results The BPRS scores were significantly improved at 12 weeks after switching to ziprasidone (F=5.96, df=2.11, p=0.003), whereas the CGI-S and GAF scores were not significantly changed. BMIs, WHRs, and TG levels were significantly decreased, with no significant changes in other lipid profiles. Conclusion Cross-tapering switching to ziprasidone is effective for patients with schizophrenia spectrum disorders. Beyond the efficacy of the procedure, favorable metabolic profiles show that switching to ziprasidone may be helpful for maintenance therapy over an extended period. KCI Citation Count: 0 |
| Author | Ko, Young-Hoon Kim, Seung-Hyun Jeong, Hyun-Ghang Jung, Han-Yong Jeon, Yang-Whan Lee, Moon-Soo Kim, Shin-Gyeom Yi, Jung-Seo Kim, Chul-Eung |
| AuthorAffiliation | 2 Department of Psychiatry, Gachon University Gil Medical Center, Incheon, Republic of Korea 3 Department of Psychiatry, Inha University Hospital, Incheon, Republic of Korea 6 Department of Psychiatry, Hallym University College of Medicine, Kangnam Sacred Heart Hospital, Seoul, Republic of Korea 1 Department of Psychiatry, Korea University College of Medicine, Ansan Hospital, Ansan, Republic of Korea 5 Department of Psychiatry, Incheon St. Mary's Hospital, The Catholic University of Korea College of Korea, Incheon, Republic of Korea 7 Department of Psychiatry, Soonchunhyang University College of Medicine, Bucheon Hospital, Bucheon, Republic of Korea 4 Department of Psychiatry, Korea University College of Medicine, Guro Hospital, Seoul, Republic of Korea |
| AuthorAffiliation_xml | – name: 2 Department of Psychiatry, Gachon University Gil Medical Center, Incheon, Republic of Korea – name: 1 Department of Psychiatry, Korea University College of Medicine, Ansan Hospital, Ansan, Republic of Korea – name: 3 Department of Psychiatry, Inha University Hospital, Incheon, Republic of Korea – name: 4 Department of Psychiatry, Korea University College of Medicine, Guro Hospital, Seoul, Republic of Korea – name: 5 Department of Psychiatry, Incheon St. Mary's Hospital, The Catholic University of Korea College of Korea, Incheon, Republic of Korea – name: 6 Department of Psychiatry, Hallym University College of Medicine, Kangnam Sacred Heart Hospital, Seoul, Republic of Korea – name: 7 Department of Psychiatry, Soonchunhyang University College of Medicine, Bucheon Hospital, Bucheon, Republic of Korea |
| Author_xml | – sequence: 1 givenname: Young-Hoon surname: Ko fullname: Ko, Young-Hoon organization: Department of Psychiatry, Korea University College of Medicine, Ansan Hospital, Ansan, Republic of Korea – sequence: 3 givenname: Chul-Eung surname: Kim fullname: Kim, Chul-Eung organization: Department of Psychiatry, Inha University Hospital, Incheon, Republic of Korea – sequence: 4 givenname: Seung-Hyun surname: Kim fullname: Kim, Seung-Hyun organization: Department of Psychiatry, Korea University College of Medicine, Guro Hospital, Seoul, Republic of Korea – sequence: 5 givenname: Yang-Whan surname: Jeon fullname: Jeon, Yang-Whan organization: Department of Psychiatry, Incheon St. Mary's Hospital, The Catholic University of Korea College of Korea, Incheon, Republic of Korea – sequence: 6 givenname: Jung-Seo surname: Yi fullname: Yi, Jung-Seo organization: Department of Psychiatry, Hallym University College of Medicine, Kangnam Sacred Heart Hospital, Seoul, Republic of Korea – sequence: 7 givenname: Moon-Soo surname: Lee fullname: Lee, Moon-Soo organization: Department of Psychiatry, Incheon St. Mary's Hospital, The Catholic University of Korea College of Korea, Incheon, Republic of Korea – sequence: 8 givenname: Shin-Gyeom surname: Kim fullname: Kim, Shin-Gyeom organization: Department of Psychiatry, Soonchunhyang University College of Medicine, Bucheon Hospital, Bucheon, Republic of Korea – sequence: 9 givenname: Hyun-Ghang surname: Jeong fullname: Jeong, Hyun-Ghang organization: Department of Psychiatry, Incheon St. Mary's Hospital, The Catholic University of Korea College of Korea, Incheon, Republic of Korea – sequence: 10 givenname: Han-Yong surname: Jung fullname: Jung, Han-Yong organization: Department of Psychiatry, Soonchunhyang University College of Medicine, Bucheon Hospital, Bucheon, Republic of Korea |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/25395978$$D View this record in MEDLINE/PubMed https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002015302$$DAccess content in National Research Foundation of Korea (NRF) |
| BookMark | eNp1kU1v1DAQhi1UREvpnRPykUuCvx1fkKptKZUqgehy4WJ5s5PGNGsHO9uK_nqcbls-JHyZkf3MvDN-X6K9EAMg9JqSWnCi3o2-ZoSKmtJa1EKaZ-iAGq0qTpjaK7nmTcVVI_bRUc7fyXw0ocq8QPtMciONbg7Q7bIHfNp10E7-BgLkjGOHFynmXC3dCMmHK3x566e2n7Mp4m9-TC77dRkG-4A_u8lDmDIuTI8vC3YXxz5B8A7H9HDhHgXwic8xrSG9Qs87N2Q4eoiH6OuH0-XiY3Xx6ex8cXxRtYKZqaJGGeBaCMN11xihidRq3XSwgkZISZQhSgM0zLCyWaekkcSwRracrkSzUvwQvd31Damz16230fn7eBXtdbLHX5bnlkkqJS_o-x06blcbWLdlq-QGOya_cennfeHfL8H3pc2NFYxJRulvrTHFH1vIk9343MIwuABxmy1V5d8FU0oW9M2fWk8ij8YUgOyAdrYiQfeEUGJn--3o7Wy_pdQKW-wvJeqfktZPxZ04T-uH_xf-AiR-tNc |
| CitedBy_id | crossref_primary_10_1093_schbul_sbaa191 |
| Cites_doi | 10.1016/j.schres.2010.05.025 10.1038/oby.2004.46 10.1097/01.jcp.0000095347.32154.08 10.1159/000328198 10.4088/JCP.0208e04 10.1097/WNF.0b013e3181d52b85 10.1016/j.pnpbp.2006.10.002 10.1038/oby.2006.252 10.1016/j.pnpbp.2010.05.010 10.1097/YIC.0b013e3280de2c7f 10.1097/YIC.0b013e32832c2624 10.1586/14737175.4.2.179 10.1016/j.pnpbp.2012.06.024 10.1176/appi.ajp.161.5.818 10.1097/YIC.0b013e3282f94905 10.1016/j.physbeh.2007.02.002 10.1056/NEJMoa051688 10.1080/15622970802269589 |
| ContentType | Journal Article |
| Copyright | Copyright © 2014 Korean Neuropsychiatric Association 2014 |
| Copyright_xml | – notice: Copyright © 2014 Korean Neuropsychiatric Association 2014 |
| DBID | AAYXX CITATION NPM 7X8 5PM ACYCR |
| DOI | 10.4306/pi.2014.11.4.459 |
| DatabaseName | CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) Korean Citation Index |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitleList | PubMed MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1976-3026 |
| EndPage | 466 |
| ExternalDocumentID | oai_kci_go_kr_ARTI_251553 PMC4225211 25395978 10_4306_pi_2014_11_4_459 |
| Genre | Journal Article |
| GrantInformation_xml | – fundername: Pfizer – fundername: Soonchunhyang University |
| GroupedDBID | --- 5-W 53G 8JR 8XY 9ZL AAKDD AAYXX ACHQT ACYCR ADBBV ADRAZ AENEX ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL CITATION DIK DU5 E3Z F5P HYE KQ8 M48 O5R O5S OK1 P5Y PGMZT RPM SJN W2D FRP M~E NPM 7X8 5PM |
| ID | FETCH-LOGICAL-c429t-1969e3744937f89470576d8febe8455069067ee8292169f659509285c31b48b63 |
| IEDL.DBID | M48 |
| ISSN | 1738-3684 |
| IngestDate | Tue Nov 21 21:33:21 EST 2023 Thu Aug 21 14:00:51 EDT 2025 Fri Jul 11 08:43:54 EDT 2025 Thu Jan 02 22:16:09 EST 2025 Tue Jul 01 02:52:55 EDT 2025 Thu Apr 24 23:00:08 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 4 |
| Keywords | Pharmacotherapy Schizophrenia Triglyceride Ziprasidone Switching |
| Language | English |
| License | http://creativecommons.org/licenses/by-nc/3.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c429t-1969e3744937f89470576d8febe8455069067ee8292169f659509285c31b48b63 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 These authors contributed equally to this work. G704-002181.2014.11.4.009 |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.4306/pi.2014.11.4.459 |
| PMID | 25395978 |
| PQID | 1625342665 |
| PQPubID | 23479 |
| PageCount | 8 |
| ParticipantIDs | nrf_kci_oai_kci_go_kr_ARTI_251553 pubmedcentral_primary_oai_pubmedcentral_nih_gov_4225211 proquest_miscellaneous_1625342665 pubmed_primary_25395978 crossref_primary_10_4306_pi_2014_11_4_459 crossref_citationtrail_10_4306_pi_2014_11_4_459 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2014-10-01 |
| PublicationDateYYYYMMDD | 2014-10-01 |
| PublicationDate_xml | – month: 10 year: 2014 text: 2014-10-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | Korea (South) |
| PublicationPlace_xml | – name: Korea (South) |
| PublicationTitle | Psychiatry investigation |
| PublicationTitleAlternate | Psychiatry Investig |
| PublicationYear | 2014 |
| Publisher | Korean Neuropsychiatric Association 대한신경정신의학회 |
| Publisher_xml | – name: Korean Neuropsychiatric Association – name: 대한신경정신의학회 |
| References | Stahl (10.4306/pi.2014.11.4.459_ref11) 2003; 64 Kim (10.4306/pi.2014.11.4.459_ref14) 2010; 33 Gaysinskaya (10.4306/pi.2014.11.4.459_ref20) 2007; 91 Komossa (10.4306/pi.2014.11.4.459_ref23) 2009 Buckley (10.4306/pi.2014.11.4.459_ref3) 2008; 69 Lindstrom (10.4306/pi.2014.11.4.459_ref8) 2001; 55 Sorensen (10.4306/pi.2014.11.4.459_ref19) 2011; 4 Weiden (10.4306/pi.2014.11.4.459_ref22) 2003; 23 American Psychiatric Association (10.4306/pi.2014.11.4.459_ref7) 1994 Malmlof (10.4306/pi.2014.11.4.459_ref21) 2006; 14 Mamo (10.4306/pi.2014.11.4.459_ref16) 2004; 161 Montes (10.4306/pi.2014.11.4.459_ref18) 2007; 31 Henderson (10.4306/pi.2014.11.4.459_ref4) 2008; 69 Stip (10.4306/pi.2014.11.4.459_ref15) 2010; 34 Na (10.4306/pi.2014.11.4.459_ref24) 2012; 39 American Diabetes Association (10.4306/pi.2014.11.4.459_ref5) 2004; 12 Alptekin (10.4306/pi.2014.11.4.459_ref9) 2009; 24 Lieberman (10.4306/pi.2014.11.4.459_ref2) 2005; 353 Ballas (10.4306/pi.2014.11.4.459_ref10) 2004; 4 Tandon (10.4306/pi.2014.11.4.459_ref1) 2010; 122 Lublin (10.4306/pi.2014.11.4.459_ref12) 2009; 10 Altamura (10.4306/pi.2014.11.4.459_ref17) 2007; 22 Lambert (10.4306/pi.2014.11.4.459_ref6) 2007; 68 Rossi (10.4306/pi.2014.11.4.459_ref13) 2008; 23 18545060 - Int Clin Psychopharmacol. 2008 Jul;23 (4):216-22 17650054 - J Clin Psychiatry. 2007;68 Suppl 6:10-3 19531959 - Int Clin Psychopharmacol. 2009 Sep;24(5):229-38 18484804 - J Clin Psychiatry. 2008;69 Suppl 1:4-17 19821380 - Cochrane Database Syst Rev. 2009 Oct 07;(4):CD006627 20470848 - Prog Neuropsychopharmacol Biol Psychiatry. 2010 Aug 16;34(6):997-1000 11860666 - Nord J Psychiatry. 2001;55 Suppl 44:5-69 22796278 - Prog Neuropsychopharmacol Biol Psychiatry. 2012 Dec 3;39(2):295-300 17690594 - Int Clin Psychopharmacol. 2007 Sep;22(5):249-67 14728084 - J Clin Psychiatry. 2003;64 Suppl 19:6-12 14981231 - Obes Res. 2004 Feb;12(2):362-8 17129654 - Prog Neuropsychopharmacol Biol Psychiatry. 2007 Mar 30;31(2):383-8 20502130 - Clin Neuropharmacol. 2010 May;33(3):121-5 15853558 - Expert Rev Neurother. 2004 Mar;4(2):179-86 17189541 - Obesity (Silver Spring). 2006 Dec;14(12):2154-62 14624190 - J Clin Psychopharmacol. 2003 Dec;23 (6):595-600 18363448 - J Clin Psychiatry. 2008 Feb;69(2):e04 18803070 - World J Biol Psychiatry. 2009;10 (4 Pt 3):710-8 16172203 - N Engl J Med. 2005 Sep 22;353(12 ):1209-23 15121646 - Am J Psychiatry. 2004 May;161(5):818-25 17383691 - Physiol Behav. 2007 May 16;91(1):142-53 20655178 - Schizophr Res. 2010 Sep;122(1-3):1-23 21577014 - Obes Facts. 2011;4(2):91-4 |
| References_xml | – volume: 122 start-page: 1 year: 2010 ident: 10.4306/pi.2014.11.4.459_ref1 publication-title: Schizophr Res doi: 10.1016/j.schres.2010.05.025 – volume: 12 start-page: 362 year: 2004 ident: 10.4306/pi.2014.11.4.459_ref5 publication-title: Obes Res doi: 10.1038/oby.2004.46 – volume: 23 start-page: 595 year: 2003 ident: 10.4306/pi.2014.11.4.459_ref22 publication-title: J Clin Psychopharmacol doi: 10.1097/01.jcp.0000095347.32154.08 – volume: 4 start-page: 91 year: 2011 ident: 10.4306/pi.2014.11.4.459_ref19 publication-title: Obes Facts doi: 10.1159/000328198 – volume: 69 start-page: e04 year: 2008 ident: 10.4306/pi.2014.11.4.459_ref4 publication-title: J Clin Psychiatry doi: 10.4088/JCP.0208e04 – start-page: CD006627 year: 2009 ident: 10.4306/pi.2014.11.4.459_ref23 publication-title: Cochrane Database Syst Rev – volume: 33 start-page: 121 year: 2010 ident: 10.4306/pi.2014.11.4.459_ref14 publication-title: Clin Neuropharmacol doi: 10.1097/WNF.0b013e3181d52b85 – volume: 31 start-page: 383 year: 2007 ident: 10.4306/pi.2014.11.4.459_ref18 publication-title: Prog Neuropsychopharmacol Biol Psychiatry doi: 10.1016/j.pnpbp.2006.10.002 – volume-title: Diagnostic and Statistical Manual of Mental Disorders year: 1994 ident: 10.4306/pi.2014.11.4.459_ref7 – volume: 14 start-page: 2154 year: 2006 ident: 10.4306/pi.2014.11.4.459_ref21 publication-title: Obesity (Silver Spring) doi: 10.1038/oby.2006.252 – volume: 34 start-page: 997 year: 2010 ident: 10.4306/pi.2014.11.4.459_ref15 publication-title: Prog Neuropsychopharmacol Biol Psychiatry doi: 10.1016/j.pnpbp.2010.05.010 – volume: 22 start-page: 249 year: 2007 ident: 10.4306/pi.2014.11.4.459_ref17 publication-title: Int Clin Psychopharmacol doi: 10.1097/YIC.0b013e3280de2c7f – volume: 69 start-page: 4 issue: Suppl 1 year: 2008 ident: 10.4306/pi.2014.11.4.459_ref3 publication-title: J Clin Psychiatry – volume: 24 start-page: 229 year: 2009 ident: 10.4306/pi.2014.11.4.459_ref9 publication-title: Int Clin Psychopharmacol doi: 10.1097/YIC.0b013e32832c2624 – volume: 4 start-page: 179 year: 2004 ident: 10.4306/pi.2014.11.4.459_ref10 publication-title: Expert Rev Neurother doi: 10.1586/14737175.4.2.179 – volume: 39 start-page: 295 year: 2012 ident: 10.4306/pi.2014.11.4.459_ref24 publication-title: Prog Neuropsychopharmacol Biol Psychiatry doi: 10.1016/j.pnpbp.2012.06.024 – volume: 68 start-page: 10 issue: Suppl 6 year: 2007 ident: 10.4306/pi.2014.11.4.459_ref6 publication-title: J Clin Psychiatry – volume: 161 start-page: 818 year: 2004 ident: 10.4306/pi.2014.11.4.459_ref16 publication-title: Am J Psychiatry doi: 10.1176/appi.ajp.161.5.818 – volume: 23 start-page: 216 year: 2008 ident: 10.4306/pi.2014.11.4.459_ref13 publication-title: Int Clin Psychopharmacol doi: 10.1097/YIC.0b013e3282f94905 – volume: 91 start-page: 142 year: 2007 ident: 10.4306/pi.2014.11.4.459_ref20 publication-title: Physiol Behav doi: 10.1016/j.physbeh.2007.02.002 – volume: 353 start-page: 1209 year: 2005 ident: 10.4306/pi.2014.11.4.459_ref2 publication-title: N Engl J Med doi: 10.1056/NEJMoa051688 – volume: 64 start-page: 6 issue: Suppl 19 year: 2003 ident: 10.4306/pi.2014.11.4.459_ref11 publication-title: J Clin Psychiatry – volume: 10 start-page: 710 year: 2009 ident: 10.4306/pi.2014.11.4.459_ref12 publication-title: World J Biol Psychiatry doi: 10.1080/15622970802269589 – volume: 55 start-page: 5 issue: Suppl 44 year: 2001 ident: 10.4306/pi.2014.11.4.459_ref8 publication-title: Nord J Psychiatry – reference: 20470848 - Prog Neuropsychopharmacol Biol Psychiatry. 2010 Aug 16;34(6):997-1000 – reference: 18803070 - World J Biol Psychiatry. 2009;10 (4 Pt 3):710-8 – reference: 14981231 - Obes Res. 2004 Feb;12(2):362-8 – reference: 18363448 - J Clin Psychiatry. 2008 Feb;69(2):e04 – reference: 14624190 - J Clin Psychopharmacol. 2003 Dec;23 (6):595-600 – reference: 19821380 - Cochrane Database Syst Rev. 2009 Oct 07;(4):CD006627 – reference: 11860666 - Nord J Psychiatry. 2001;55 Suppl 44:5-69 – reference: 18545060 - Int Clin Psychopharmacol. 2008 Jul;23 (4):216-22 – reference: 20655178 - Schizophr Res. 2010 Sep;122(1-3):1-23 – reference: 22796278 - Prog Neuropsychopharmacol Biol Psychiatry. 2012 Dec 3;39(2):295-300 – reference: 19531959 - Int Clin Psychopharmacol. 2009 Sep;24(5):229-38 – reference: 15853558 - Expert Rev Neurother. 2004 Mar;4(2):179-86 – reference: 20502130 - Clin Neuropharmacol. 2010 May;33(3):121-5 – reference: 14728084 - J Clin Psychiatry. 2003;64 Suppl 19:6-12 – reference: 18484804 - J Clin Psychiatry. 2008;69 Suppl 1:4-17 – reference: 17189541 - Obesity (Silver Spring). 2006 Dec;14(12):2154-62 – reference: 21577014 - Obes Facts. 2011;4(2):91-4 – reference: 16172203 - N Engl J Med. 2005 Sep 22;353(12 ):1209-23 – reference: 17129654 - Prog Neuropsychopharmacol Biol Psychiatry. 2007 Mar 30;31(2):383-8 – reference: 17383691 - Physiol Behav. 2007 May 16;91(1):142-53 – reference: 17650054 - J Clin Psychiatry. 2007;68 Suppl 6:10-3 – reference: 15121646 - Am J Psychiatry. 2004 May;161(5):818-25 – reference: 17690594 - Int Clin Psychopharmacol. 2007 Sep;22(5):249-67 |
| SSID | ssj0000070169 |
| Score | 1.9561298 |
| Snippet | Switching antipsychotics is one useful therapeutic option when the treatment of schizophrenia encounters suboptimal efficacy and intolerability issues. This... Objective Switching antipsychotics is one useful therapeutic option when the treatment of schizophrenia encounters suboptimal efficacy and intolerability... |
| SourceID | nrf pubmedcentral proquest pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 459 |
| SubjectTerms | Original 정신과학 |
| Title | The Effectiveness of Cross-Tapering Switching to Ziprasidone in Patients with Schizophrenia or Schizoaffective Disorder |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/25395978 https://www.proquest.com/docview/1625342665 https://pubmed.ncbi.nlm.nih.gov/PMC4225211 https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002015302 |
| Volume | 11 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| ispartofPNX | PSYCHIATRY INVESTIGATION, 2014, 11(4), , pp.459-466 |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bS8MwFA5eQHwR787LiOCLD51dkzbpk4goKkyEORBfQi-plo22dh3qv_ecXuaU4YNPgy5ptpyTnu9rTr5DyIkZchZpHRkQPF2DO0wb0na5EZqBaYXAibqllFLv3rkZ8Lsn--n7eHQ9geO51A7rSQ3yUefj7fMcFjzg1w4HxHuWxZiixWH1d3iH2-4iWYa45CAV69VgvwLDAqVHyhOSsMqZI3m1bzn3JqgSbDPXLguwzYSsxSSP5qHR30mVM1Hqep2s1fCSXlT-sEEWdLJJVnr1BvoWeQe3oJVicf2Yo2lEL3Fc49HLSl1C2n-PizLFkhYpfY6z3AOXTRNN44Q-VDqsY4ovcGl_NmWPpnl9wWsGoI245zYZXF89Xt4Yde0FI4AIVRiomqOZ4BzgSyRdLgDXOaGMwOYSD0KjvrHQWlquBXMaoSqh6VrSDljX59J32A5ZSuCX7RGqBcAAzwcqIkyupSMhZvqChdBH2IGvW-SsmV4V1MLkWB9jpICgoG1UFiu0DbAVxRXYpkVOpz2ySpTjj7bHYDE1DGKFStr4-ZKqYa6AL9wqCyvcMGjT2FPB6sItEy_R6WSsukAPGYIYu0V2K_tOR2zco0XED8tPG-B4P79J4tdSwZvDUxSY9_6_ex6QVfyXVVbhIVkq8ok-AnRU-O3S6dvla6svCNUMFw |
| linkProvider | Scholars Portal |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+Effectiveness+of+Cross-Tapering+Switching+to+Ziprasidone+in+Patients+with+Schizophrenia+or+Schizoaffective+Disorder&rft.jtitle=Psychiatry+investigation&rft.au=Ko%2C+Young-Hoon&rft.au=Na%2C+Kyoung-Sae&rft.au=Kim%2C+Chul-Eung&rft.au=Kim%2C+Seung-Hyun&rft.date=2014-10-01&rft.pub=Korean+Neuropsychiatric+Association&rft.issn=1738-3684&rft.eissn=1976-3026&rft.volume=11&rft.issue=4&rft.spage=459&rft.epage=466&rft_id=info:doi/10.4306%2Fpi.2014.11.4.459&rft_id=info%3Apmid%2F25395978&rft.externalDocID=PMC4225211 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1738-3684&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1738-3684&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1738-3684&client=summon |